EUVIMED · CrossrefJournal
Blood Immunology & Cellular Therapy
ISSN 3050-5976 · Elsevier BV
Latest articles
Should frontline Hodgkin lymphoma therapy differ based on validated genetic, immunologic, or biochemical biomarkers?
Long-acting IL-7 (NT-I7, efineptakin alfa) after CD19 CAR T-cell therapy for large B-cell lymphoma: a phase 1b trial
False Positive HIV-1 NAAT screening results after CAR-T therapy: A single institution, retrospective study
Polarized CAR-T9 immunotherapy prolongs B-cell depletion in a mouse model of systemic lupus erythematosus
Heme-Induced Terminal Differentiation Impairs CAR T Cell Fitness
Real-world experience of anakinra prophylaxis in CAR-T
Harnessing Antibody-Dependent Cellular Phagocytosis in Human iPSC-Derived Macrophages for Cancer Therapy
Plasma proteomics reveals a low-expression immune phenotype in long-term pediatric hematopoietic cell transplantation survivors
Duffy null status predicts severe neutropenia after ciltacabtagene autoleucel but not other BCMA therapies in myeloma
Expansion of minor PNH-phenotype cell populations within myeloid progenitors after CAR T-cell therapy
Anti-CD38 therapy for the treatment of autoimmune neutropenia
Development of TCR-NK cells as an off-the-shelf cell therapy against HCMV
Preapheresis clinical patient profiles predict patient’s manufacturing fitness and efficacy with idecabtagene vicleucel
Disarming the natural killers: mechanisms of NK cell dysfunction in hematological malignancies
Adoptive transfer of regulatory T cells in pediatric patients with treatment-refractory acute graft-versus-host disease
Infections following CAR T-cell therapies in children, adolescents, and young adults: a systematic review and meta-analysis
CD20×CD3 bispecific antibodies as bridging to CAR-T in aggressive B-cell lymphomas: a single-institution experience
Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART
Tabelecleucel as a bridge to hematopoietic stem cell transplant in systemic chronic active Epstein-Barr virus disease
Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM
Dosing patterns for talquetamab, including dose deescalation, in a real-world setting
Plasma proteomics and single-cell RNA-seq identify cellular and soluble mechanisms of graft rejection after HSCT
Graft-versus-host disease after chimeric antigen receptor T-cell therapy
Clinical-grade armored BCMA CAR T cells overcome TGF-β–mediated immunosuppression in multiple myeloma
Lisocabtagene maraleucel outcome in large B-cell lymphoma associates with memory composition and mitochondrial fitness of T cells
Outpatient bispecific step-up dosing with prophylactic dexamethasone: impact on resource utilization and estimated cost
Prognostic nutritional index and geriatric nutritional risk index in lisocabtagene maraleucel for B-cell lymphoma
Outcomes and engraftment syndrome after TLI-based autologous stem cell transplant for Hodgkin lymphoma in the era of CPI
Decentralized CAR-T manufacturing: highlighting regulatory pathways in the United States and abroad
Precision editing of cyclophilin A generates cyclosporine- and voclosporin-resistant cellular therapies
EUVIMED